Related Experiment Video
Updated: Jun 25, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Monoclonal antibody therapies for solid tumors
Dimiter V Tassev1, Nai-Kong V Cheung
11Gerstner Sloan-Kettering Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Background:
About 1.4 million new cancer cases are expected to be diagnosed in the US in 2008 and the overall costs of cancer treatment is estimated at > $200 billion per year. Over half a million people will die from cancer each year. Monoclonal antibodies have attracted attention because of their potential clinical benefits. Currently, there are four monoclonal antibodies that have been approved by the FDA for the treatment of solid tumor malignancies. Over 100 other antibodies are in early- and late-phase clinical testing.
Objectives/Methods:
Clinical efficacy of FDA-approved and investigational monoclonal antibody therapies are summarized.
Results/Conclusions:
Anti-tumor responses have been modest. However, the advent of novel antibody engineering and combination therapy strategies has generated much optimism for current and future antibody-based therapeutics in solid tumors.
Insights
Monoclonal antibody therapies show modest anti-tumor responses in solid tumors but offer hope. Novel engineering and combination strategies are advancing antibody-based cancer treatments.
Area of Science:
- Oncology
- Immunotherapy
- Drug Development
Background:
- Cancer remains a leading cause of death, with significant economic burden.
- Monoclonal antibodies (mAbs) are a promising therapeutic class for solid tumors.
- Four mAbs are FDA-approved for solid tumors, with over 100 in clinical trials.
Purpose of the Study:
- To summarize the clinical efficacy of FDA-approved and investigational monoclonal antibody therapies.
- To provide an overview of the current landscape of antibody-based cancer treatments.
Main Methods:
- Review of clinical efficacy data for approved and investigational monoclonal antibodies.
- Summary of therapeutic strategies involving monoclonal antibodies in solid tumors.
Main Results:
- Current anti-tumor responses for monoclonal antibody therapies have been modest.
- Significant ongoing research and development in antibody engineering and combination therapies.
Conclusions:
- Despite modest current responses, monoclonal antibodies hold promise for future cancer therapeutics.
- Advancements in antibody engineering and combination strategies are key to improving efficacy in solid tumors.
More Related Videos
08:53In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...